milnacipran pierre fabre medicament
pierre fabre medicament - milnacipran - fibromialgija
hemangiol
pierre fabre medicament - propranolol hidroklorid - hemangioma - beta blokatorji - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
willefact 1000 i.e. prašek in vehikel za raztopino za injiciranje
lfb biomedicaments - von willebrandov faktor, humani - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 1000 i.e. / 1 viala - von willebrandov faktor
willefact 2000 i.e. prašek in vehikel za raztopino za injiciranje
lfb biomedicaments - von willebrandov faktor, humani; voda za injekcije - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 2000 i.e. / 1 viala voda za injekcije20 i.e. / 1 viala; voda za injekcije 20 i.e. / 1 viala - von willebrandov faktor
willefact 500 i.e. prašek in vehikel za raztopino za injiciranje
lfb biomedicaments - von willebrandov faktor, humani; voda za injekcije - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 500 i.e. / 1 viala voda za injekcije5 i.e. / 1 viala; voda za injekcije 5 i.e. / 1 viala - von willebrandov faktor
tardyferon 80 mg obložene tablete
pierre fabre mÉdicament - železov(ii) sulfat - filmsko obložena tableta - železov(ii) sulfat 80 mg / 1 tableta - železov(ii) sulfat
abiraterone krka
krka, d.d., novo mesto - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
impulsor
pierre fabre medicament - milnacipran - fibromialgija
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastična sredstva - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
mektovi
pierre fabre medicament - binimetinib - melanoma - antineoplastična sredstva - binimetinib v kombinaciji z encorafenib je indiciran za zdravljenje odraslih bolnikov z unresectable ali metastatskega melanoma z braf v600 mutacija.